Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 89.96 Billion KRW | 12.41% |
| 2022 | 80.03 Billion KRW | 0.9% |
| 2021 | 79.32 Billion KRW | 3.63% |
| 2020 | 76.54 Billion KRW | 0.52% |
| 2019 | 76.14 Billion KRW | 3.64% |
| 2018 | 73.47 Billion KRW | 14.59% |
| 2017 | 64.11 Billion KRW | 12.81% |
| 2016 | 56.83 Billion KRW | -2.88% |
| 2015 | 58.51 Billion KRW | 5.88% |
| 2014 | 55.26 Billion KRW | 6.07% |
| 2013 | 52.1 Billion KRW | -3.69% |
| 2012 | 54.1 Billion KRW | -5.16% |
| 2011 | 57.04 Billion KRW | 31.59% |
| 2010 | 43.34 Billion KRW | -0.92% |
| 2009 | 43.75 Billion KRW | 25.82% |
| 2008 | 34.77 Billion KRW | 5.86% |
| 2007 | 32.84 Billion KRW | 4.2% |
| 2006 | 31.52 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 93.6 Billion KRW | 4.04% |
| 2024 Q2 | 99.15 Billion KRW | 6.24% |
| 2023 Q4 | 89.96 Billion KRW | -5.33% |
| 2023 Q2 | 93.77 Billion KRW | -1.62% |
| 2023 FY | 89.96 Billion KRW | 12.41% |
| 2023 Q1 | 95.32 Billion KRW | 19.1% |
| 2023 Q3 | 95.02 Billion KRW | 1.34% |
| 2022 Q3 | 84.62 Billion KRW | -1.75% |
| 2022 Q1 | 90.2 Billion KRW | 13.72% |
| 2022 FY | 80.03 Billion KRW | 0.9% |
| 2022 Q2 | 86.13 Billion KRW | -4.51% |
| 2022 Q4 | 80.03 Billion KRW | -5.43% |
| 2021 Q4 | 79.32 Billion KRW | 4.61% |
| 2021 FY | 79.32 Billion KRW | 3.63% |
| 2021 Q1 | 85.44 Billion KRW | 11.64% |
| 2021 Q2 | 78.11 Billion KRW | -8.59% |
| 2021 Q3 | 75.82 Billion KRW | -2.92% |
| 2020 FY | 76.54 Billion KRW | 0.52% |
| 2020 Q1 | 83.73 Billion KRW | 9.97% |
| 2020 Q3 | 75.77 Billion KRW | -2.74% |
| 2020 Q4 | 76.54 Billion KRW | 1.01% |
| 2020 Q2 | 77.91 Billion KRW | -6.96% |
| 2019 Q4 | 76.14 Billion KRW | 4.05% |
| 2019 FY | 76.14 Billion KRW | 3.64% |
| 2019 Q1 | 80.5 Billion KRW | 9.58% |
| 2019 Q2 | 72.01 Billion KRW | -10.55% |
| 2019 Q3 | 73.18 Billion KRW | 1.63% |
| 2018 Q3 | 70.84 Billion KRW | 0.99% |
| 2018 Q1 | 70.28 Billion KRW | 9.63% |
| 2018 Q2 | 70.14 Billion KRW | -0.2% |
| 2018 FY | 73.47 Billion KRW | 14.59% |
| 2018 Q4 | 73.47 Billion KRW | 3.71% |
| 2017 Q1 | 59.73 Billion KRW | 5.1% |
| 2017 Q4 | 64.11 Billion KRW | 18.34% |
| 2017 Q3 | 54.17 Billion KRW | 1.99% |
| 2017 Q2 | 53.12 Billion KRW | -11.07% |
| 2017 FY | 64.11 Billion KRW | 12.81% |
| 2016 Q1 | 65.18 Billion KRW | 0.0% |
| 2016 Q4 | 56.83 Billion KRW | -4.13% |
| 2016 Q3 | 59.28 Billion KRW | 0.46% |
| 2016 Q2 | 59 Billion KRW | -9.47% |
| 2016 FY | 56.83 Billion KRW | -2.88% |
| 2015 Q2 | 51.77 Billion KRW | -10.79% |
| 2015 Q1 | 58.03 Billion KRW | 5.01% |
| 2015 Q3 | 53.22 Billion KRW | 2.81% |
| 2015 FY | 58.51 Billion KRW | 5.88% |
| 2014 Q1 | 58.71 Billion KRW | 12.69% |
| 2014 Q2 | 55.44 Billion KRW | -5.56% |
| 2014 FY | 55.26 Billion KRW | 6.07% |
| 2014 Q4 | 55.26 Billion KRW | -2.69% |
| 2014 Q3 | 56.79 Billion KRW | 2.43% |
| 2013 FY | 52.1 Billion KRW | -3.69% |
| 2013 Q2 | 59.23 Billion KRW | 2.63% |
| 2013 Q1 | 57.71 Billion KRW | 6.68% |
| 2013 Q4 | 52.1 Billion KRW | 3.31% |
| 2013 Q3 | 50.43 Billion KRW | -14.86% |
| 2012 Q4 | 54.1 Billion KRW | 0.0% |
| 2012 FY | 54.1 Billion KRW | -5.16% |
| 2012 Q1 | 52.67 Billion KRW | 0.0% |
| 2011 Q1 | 57.62 Billion KRW | 32.93% |
| 2011 Q2 | 55.77 Billion KRW | -3.21% |
| 2011 Q3 | 53.67 Billion KRW | -3.76% |
| 2011 FY | 57.04 Billion KRW | 31.59% |
| 2010 Q4 | 43.34 Billion KRW | 4.65% |
| 2010 Q1 | 44.14 Billion KRW | 0.91% |
| 2010 FY | 43.34 Billion KRW | -0.92% |
| 2010 Q2 | 42.88 Billion KRW | -2.88% |
| 2010 Q3 | 41.42 Billion KRW | -3.41% |
| 2009 Q3 | 42 Billion KRW | -3.02% |
| 2009 Q4 | 43.75 Billion KRW | 4.16% |
| 2009 Q2 | 43.31 Billion KRW | 11.07% |
| 2009 Q1 | 38.99 Billion KRW | 12.15% |
| 2009 FY | 43.75 Billion KRW | 25.82% |
| 2008 Q2 | 36.49 Billion KRW | -2.3% |
| 2008 Q3 | 37.21 Billion KRW | 1.96% |
| 2008 Q1 | 37.35 Billion KRW | 0.0% |
| 2008 FY | 34.77 Billion KRW | 5.86% |
| 2008 Q4 | 34.77 Billion KRW | -6.55% |
| 2007 Q2 | 36.04 Billion KRW | 0.0% |
| 2007 Q3 | 35.32 Billion KRW | -2.0% |
| 2007 FY | 32.84 Billion KRW | 4.2% |
| 2006 FY | 31.52 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -15.551% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 90.324% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 87.277% |
| HANDOK Inc. | 449.7 Billion KRW | 79.995% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -5.013% |
| Yuhan Corporation | 712.33 Billion KRW | 87.37% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 85.763% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -466.016% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 89.439% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -68.07% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 56.301% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -19.681% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | 39.128% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -27.789% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -15.551% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -146.912% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | 64.179% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | 59.237% |
| JW Holdings Corporation | 827.51 Billion KRW | 89.128% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 79.413% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 84.668% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 76.3% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -13.447% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -28.581% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | 62.955% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | 72.762% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -15.551% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 81.64% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 89.515% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 76.3% |
| Yuhan Corporation | 712.33 Billion KRW | 87.37% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 81.171% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | 34.317% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 82.587% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 76.3% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | 41.784% |
| CKD Bio Corp. | 170.76 Billion KRW | 47.315% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | 63.089% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | 42.936% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -109.129% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -13.447% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 85.777% |
| Boryung Corporation | 373.1 Billion KRW | 75.888% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | 56.788% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | 56.301% |
| JW Lifescience Corporation | 96.44 Billion KRW | 6.717% |